Idiopathic Pulmonary Fibrosis clinical trials at UC Davis
2 research studies open to eligible people
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 40 years and up
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Sacramento, California and other locations
Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 40 years and up
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Sacramento, California and other locations
Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include Timothy Albertson, MD.